Mast cells and gastrointestinal dysmotility in the cystic fibrosis mouse

PLoS ONE

Volumn 4, Issue 1, 2009, Pages

  de Lisle, Robert C ^a   Meldi, Lauren ^a   Roach, Eileen ^a   Flynn, Maureen ^a   Sewell, Racquel ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPOUND 48-80; CROMOGLYCATE DISODIUM; DOXANTRAZOLE; KETOTIFEN; THIOXANTHENE DERIVATIVE; TRANSMEMBRANE CONDUCTANCE REGULATOR; XANTHONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL STIMULATION; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; GASTROINTESTINAL MOTILITY DISORDER; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INTESTINE TRANSIT TIME; MALE; MAST CELL; MOUSE; NONHUMAN; STOMACH EMPTYING; WILD TYPE; ANIMAL; C57BL MOUSE; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRANSIT; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SMALL INTESTINE; STOMACH; TRANSGENIC MOUSE;

MUS;

ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE MODELS, ANIMAL; GASTRIC EMPTYING; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRANSIT; IMMUNITY, INNATE; INTESTINE, SMALL; MAST CELLS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; STOMACH; THIOXANTHENES; XANTHONES;

EID: 59349099345     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004283     Document Type: Article

References (41)

1. De Lisle RC, Roach E, Jansson K (2007) Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 293: G577-G584.
2. Serna H, Porras M, Vergara P (2006) Mast Cell Stabilizer Ketotifen [4-(1-Methyl-4-piperidylidene)-4H-benzo[4,5]cyclohepta[1,2-b]thiophen- 10(9 H)-one Fumarate] Prevents Mucosal Mast Cell Hyperplasia and Intestinal Dysmotility in Experimental Trichinella spiralis Inflammation in the Rat. J Pharmacol Exp Ther 319: 1104-1111.
3. Schwarz NT, Kalff JC, Turler A, Speidel N, Grandis JR, et al. (2004) Selective jejunal manipulation causes postoperative pan-enteric inflammation and dysmotility. Gastroenterology 126: 159-169.
4. Raia V, Maiuri L, De Ritis G, De Vizia B, Vacca L, et al. (2000) Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients. Pediatr Res 47: 344-350.
5. Smyth RL, Croft NM, O'Hea U, Marshall TG, Ferguson A (2000) Intestinal inflammation in cystic fibrosis. Arch Dis Child 82: 394-399.
6. Bruzzese E, Raia V, Gaudiello G, Polito G, Buccigrossi V, et al. (2004) Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther 20: 813-819.
7. Fridge JL, Conrad C, Gerson L, Castillo RO, Cox K (2007) Risk factors for small bowel bacterial overgrowth in cystic fibrosis. J Pediatr Gastroenterol Nutr 44: 212-218.
8. Lewindon PJ, Robb TA, Moore DJ, Davidson GP, Martin AJ (1998) Bowel dysfunction in cystic fibrosis: importance of breath testing. J Paediatr Child Health 34: 79-82.
9. Bali A, Stableforth DE, Asquith P (1983) Prolonged small-intestinal transit time in cystic fibrosis. Br Med J (Clin Res Ed) 287: 1011-1013.
10. Dalzell AM, Heaf DP (1990) Oro-caecal transit time and intra-luminal pH in cystic fibrosis patients with distal intestinal obstruction syndrome. Acta Univ Carol [Med] (Praha) 36: 159-160.
11. Dalzell AM, Freestone NS, Billington D, Heaf DP (1990) Small intestinal permeability and orocaecal transit time in cystic fibrosis. Arch Dis Child 65: 585-588.
12. Escobar H, Perdomo M, Vasconez F, Camarero C, del Olmo MT, et al. (1992) Intestinal permeability to 51Cr-EDTA and orocecal transit time in cystic fibrosis. J Pediatr Gastroenterol Nutr 14: 204-207.
13. Murphy MS, Brunetto AL, Pearson AD, Ghatei MA, Nelson R, et al. (1992) Gut hormones and gastrointestinal motility in children with cystic fibrosis. Dig Dis Sci 37: 187-192.
14. Gregory PC (1996) Gastrointestinal pH, motility/transit and permeability in cystic fibrosis. J Pediatr Gastroenterol Nutr 23: 513-523.
15. De Lisle RC (2007) Altered Transit and Bacterial Overgrowth in the Cystic Fibrosis Mouse Small Intestine. Am J Physiol Gastrointest Liver Physiol 293: G104-G111.
16. Norkina O, Burnett TG, De Lisle RC (2004) Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun 72: 6040-6049.
17. Norkina O, Kaur S, Ziemer D, De Lisle RC (2004) Inflammation of the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 286: G1032-G1041.
18. Barbara G, Stanghellini V, De Giorgio R, Corinaldesi R (2006) Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil 18: 6-17.
19. Wood JD (2007) Effects of bacteria on the enteric nervous system: implications for the irritable bowel syndrome. J Clin Gastroenterol 41: S7-19.
20. Goldhill JM, Finkelman FD, Morris SC, Shea-Donohue T (1995) Neural control of mouse small intestinal longitudinal muscle: interactions with inflammatory mediators. J Pharmacol Exp Ther 274: 72-77.
21. Wang XY, Zarate N, Soderholm JD, Bourgeois JM, Liu LW (2007) Ultrastructural injury to interstitial cells of Cajal and communication with mast cells in Crohn's disease. Neurogastroenterol Motil 19: 349-364.
22. Fargeas MJ, Theodourou V, Fioramonti J, Bueno L (1992) Relationship between mast cell degranulation and jejunal myoelectric alterations in intestinal anaphylaxis in rats. Gastroenterology 102: 157-162.
23. De Schepper HU, De Man JG, Moreels TG, Pelckmans PA, De Winter BY (2008) Review article: gastrointestinal sensory and motor disturbances in inflammatory bowel disease-clinical relevance and pathophysiological mechanisms. Aliment Pharmacol Ther 27: 621-637.
24. Van Nassauw L, Adriaensen D, Timmermans JP (2007) The bidirectional communication between neurons and mast cells within the gastrointestinal tract. Auton Neurosci 133: 91-103.
25. Sand E, Themner-Persson A, Ekblad E (2008) Mast cells reduce survival of myenteric neurons in culture. Neuropharmacology (Epub ahead of print).
26. De Lisle RC, Isom KS, Ziemer D, Cotton CU (2001) Changes in the exocrine pancreas secondary to altered small intestinal function in the CF mouse. Am J Physiol Gastrointest Liver Physiol 281: G899-G906.
27. Eckman EA, Cotton CU, Kube DM, Davis PB (1995) Dietary changes improve survival of CFTR S489X homozygous mutant mouse. Am J Physiol Lung Cell Mol Physiol 269: L625-L630.
28. Kalia N, Bardhan KD, Reed MW, Jacob S, Brown NJ (2000) Mast cell stabilization prevents ethanol-induced rat gastric mucosal injury: mechanisms of protection. J Gastroenterol Hepatol 15: 133-141.
29. Steiner DRS, Gonzalez NC, Wood JG (2003) Mast cells mediate the microvascular inflammatory response to systemic hypoxia. J Appl Physiol 94: 325-334.
30. Szabo A, Boros M, Kaszaki J, Nagy S (1997) The role of mast cells in mucosal permeability changes during ischemia-reperfusion injury of the small intestine. Shock 8: 284-291.
31. Brown JF, Chafee KA, Tepperman BL (1998) Role of mast cells, neutrophils and nitric oxide in endotoxin-induced damage to the neonatal rat colon. Br J Pharmacol 123: 31-38.
32. Scott RB, Maric M (1993) Mediation of anaphylaxis-induced jejunal circular smooth muscle contraction in rats. Dig Dis Sci 38: 396-402.
33. Gersch C, Dewald O, Zoerlein M, Michael LH, Entman ML, et al. (2002) Mast cells and macrophages in normal C57/BL/6 mice. Histochem Cell Biol 118: 41-49.
34. Braga T, Grujic M, Lukinius A, Hellman L, Abrink M, et al. (2006) Serglycin proteoglycan is required for secretory granule integrity in mucosal mast cells. Biochem J 403: 49-57.
35. Stevens RL, Adachi R (2007) Protease-proteoglycan complexes of mouse and human mast cells and importance of their beta-tryptase-heparin complexes in inflammation and innate immunity. Immunol Rev 217: 155-167.
36. Knight PA, Brown JK, Wright SH, Thornton EM, Pate JA, et al. (2007) Aberrant mucosal mast cell protease expression in the enteric epithelium of nematode-infected mice lacking the integrin alphavbeta6, a transforming growth factor-beta1 activator. Am J Pathol 171: 1237-1248.
37. Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, et al. (2005) Mast Cell-Deficient W-sash c-kit Mutant KitW-sh/W-sh Mice as a Model for Investigating Mast Cell Biology in Vivo. Am J Pathol 167: 835-848.
38. Scudamore CL, McMillan L, Thornton EM, Wright SH, Newlands GF, et al. (1997) Mast cell heterogeneity in the gastrointestinal tract: variable expression of mouse mast cell protease-1 (mMCP-1) in intraepithelial mucosal mast cells in nematode-infected and normal BALB/c mice. Am J Pathol 150: 1661-1672.
39. Welle M (1997) Development, significance, and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase. J Leukoc Biol 61: 233-245.
40. Friend DS, Ghildyal N, Austen KF, Gurish MF, Matsumoto R, et al. (1996) Mast cells that reside at different locations in the jejunum of mice infected with Trichinella spiralis exhibit sequential changes in their granule ultrastructure and chymase phenotype. J Cell Biol 135: 279-290.
41. Metcalfe DD, Baram D, Mekori YA (1997) Mast cells. Physiol Rev 77: 1033-1079.